We aim to provide members with both general and haematology specific up-to-date COVID-19 information. This advice is for healthcare professionals. Patients looking for further information on their condition are advised to speak to their healthcare providers, who are best placed to answer specific questions. Patients may also be able to get information from their patient support groups, some of them can be found listed here.
Media Statement on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus vaccination
The Expert Haematology Panel has been instrumental in describing this condition and its management and continues to work closely with PHE and regulatory authorities. BSH is working with the EHP to make sure the haematology community is kept up to date with the latest information on this syndrome. We have received many requests from the media for information and interviews and we continue to do our best to advise and inform wherever possible. However, all our members have responsibilities as NHS clinicians which are their priority roles and if we are unable to respond further, media requests may be redirected to MHRA.
This page will be reviewed every day and updated as necessary. If you would like to add any resources please contact: Saskia@b-s-h.org.uk
Vaccine-induced immune thrombocytopenia and thrombosis: Link to guidance on management provided by the Expert Haematology Panel.
The Expert Haematology Panel comprises specialists in immunohaematology, haemostasis and thrombosis (or blood clotting and immune causes of reduced platelets), who held daily meetings between March and July 2021, to support clinicians managing these patients and learn from new cases. They are in regular communication with the regulators, other UK medical and surgical societies, multidisciplinary groups and international haematology colleagues focussed on this condition.
The meetings continue, now only on Mondays at 2pm, on this link
Media Statement on the syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus vaccination
The Expert Haematology Panel has been instrumental in describing this condition and its management and continues to work closely with PHE and regulatory authorities. BSH is working with the EHP to make sure the haematology community is kept up to date with the latest information on this syndrome. We have received many requests from the media for information and interviews and we continue to do our best to advise and inform wherever possible. However, all our members have responsibilities as NHS clinicians which are their priority roles and if we are unable to respond further, media requests may be redirected to MHRA
Guidance produced by the UK ITP Forum Working Party on ITP/ITP relapse following Covid-19 vaccination.
There is now emerging evidence of a small risk of ITP or ITP relapse following Covid-19 vaccination. The UK ITP Forum has produced guidance for clinicians managing such cases. This is a live document subject to updates as more is learnt about the condition. Additionally, Public Health England (PHE) are collecting data on this post-vaccine complication in order to better understand it’s clinical history as well as the safety of giving a further Covid-19 vaccine.
Please follow this link to complete the PHE survey
The Joint Committee on Vaccination and Immunisation (JCVI) has issued updated guidance in relation to COVID-19 vaccinations for individuals aged 12 years and over with severe immunosuppression. This letter sets out the actions we are asking systems to take from today to begin vaccinating this group with a third dose as part of their primary vaccination course by 13 September 2021.
VITT is a rare disorder occurring after COVID-19 vaccination and leading to blood clots in multiple organ sites including the venous sinuses of the brain. Untreated the risk of death is over 50%. People who have previously had VITT may present with recurrent symptoms. They need to be monitored closely.
This document outlines the Haematology triage policy for patients with previous vaccine-induced immune thrombocytopenia and thrombosis (VITT)
A list of UK Laboratories Offering HIT ELISA testing can be found here.
This is a leaflet that can be printed out and given to patients.
COVID-19 vaccine in patients with haematological disorders
British Society for Haematology
This statement has been produced by the British Society for Haematology and has been reviewed by the Intercollegiate Committee on Haematology, on behalf of the Royal College of Physicians of London and the Royal College of Pathologists. Specialist haematology groups have also contributed.
King’s College Hospital has released guidance for treating adult aplastic anaemia/bone marrow failure patients during the COVID-19 outbreak.
King's College Hospital has also created a brief data questionnaire for any AA patient in the UK who develops the COVID-19 infection. It is important to capture data in a systematic way on all aplastic anaemia(AA) patients with COVID-19 so that we can learn about the true impact of this virus in this group of patients.
The BJHaem have published open-access articles about COVID-19.
Click the links below to read these articles
This is the BSH guidance on B12 supplements during COVID pandemic.
These documents were made in a collaboration between the Haemoglobinopathy Co-ordinating Centres in England, offering guidance to health professionals working with patients with Diamond Blackfan anaemia (DBA). It has been reviewed and agreed by representatives of the Haemoglobinopathy Co-ordinating Centres in England and the Clinical Reference Group for Haemoglobin disorders and DBA(UK).
Click the links below to download advice:
The European Gaucher Disease Network, an EHA SWG GD Task Force, have written a response to the current SARS-‐CoV2 (COVID-19) infection.
The UK ITP Forum, has provided information for adult patients with immune thrombocytopenia in the setting of COVID-19.
Practical guidance has been developed for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.
NICE new guidelines cover the management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.
It should be noted that due to the need to publish these very rapidly they have not gone through the usual NICE guidance development process.
This is a morphology update article, about a recent case of Plasmacytoid lymphocytes in a patient with COVID-19. It was written by Barbara J. Bain, David Foldes, Richard Hinton and Siamak Arami.
The British Society for Haematology Guidance on shielding for Children and Adults with splenectomy or splenic dysfunction during the COVID-19 pandemic.
Please see our guidance here
Along with many other Specialist Societies, BSH has been working with the Royal College of Physicians to highlight the issues of re-provisioning services in the presence of an ongoing COVID-19 risk.
The following brief summary document has been submitted to RCP and used to inform discussions at a senior level in the Department of Health.
A statement has been released from the Haemoglobinopathy Co-ordinating Centres.
Guidance regarding iron chelation therapy in patients haemoglobin disorders or rare anaemias and cardiac iron overload if unwell with presumed or confirmed COVID-19 infection.
National Haemoglobinopathy Panel Patient information on COVID-19 in haemoglobinopathy and rare inherited anaemia patients is here.
Guidance on supporting the transfusion needs of patients with inherited red cell disorders during the COVID-19 pandemic in England.
This information has been produced following virtual meetings with representatives from the Haemoglobinopathy Co-ordinating Centres (HCCs) for Haemoglobin Disorders, the Clinical Reference Group for Haemoglobin Disorders, the National Haemoglobinopathy Panel, NHS Screening Committee and NHSBT as well as national experts on Sickle Cell Disease, Thalassaemia and Rare Anaemias and patient groups. The topics covered include: 1. Updated shielding advice 2. General advice 3. Inpatient care 4. Day care management 5. Outpatient care and care of long term complications 6. Hydroxycarbamide 7. Annual Reviews 8. Trans-cranial Doppler (TCD) screening 9. Multi-specialist clinics 10. Off-site clinics 11. Management of iron overload 12. Multi-disciplinary meetings 13. Transition 14. Psychology support 15. Community services 16. Education 17. Research 18. Additional advice on management of thalassaemia and rare anaemias 19. Management of patients who have had a Haematopoetic Stem Cell Transplantation /Gene therap
Blood Cancer UK's brand NEW webpages for all healthcare professionals working in haemato-oncology are now live.
- Coronavirus resources for healthcare professionals
- Guidance for managing haemato-oncology patients
- Learning resources for those new to haematology
- Managing healthcare professionals’ health and well-being
- Facilitating conversations around Advance Care Plannng
This is a letter that BCUK has written to haematology teams and GPs to highlight that Blood Cancer patients need to know that the covid-19 vaccine may not work for them.
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic
Previously, the European Society of Medical Oncology (ESMO) had established cancer patient management during the coronavirus disease 2019 (COVID-19) pandemic.1 These recommendations should be used as guidance for prioritizing the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.
The British Society of Blood and Marrow Transplantation and Cellular Therapy(BSBMTCT) have created recommendations for adult patients with COVID-19.
The National Cancer Research Institute (NCRI) has created COVID-19 (coronavirus) advice for patients with Chronic Myeloid Leukaemia receiving TKI therapy.
The European Society for Blood and Marrow Transplantation (EBMT) have issued recommendations for recipients and donors of hematopoietic cells before the beginning of any of the transplant procedures (mobilization, apheresis, marrow harvest, conditioning). These guidelines will be updated when new information is obtained about COVID-19 epidemiology and clinical outcome.
To read more from the EBMT, please click link below:
MPN Voice provides information and emotional support to everyone who has been diagnosed with a myeloproliferative neoplasm (MPN) and their families. Therefore, like many other organizations during the COVID-19 outbreak, MPN Voice are providing people with information issued by the NHS and the Government.
The UK/Ireland Paediatric BMT group has created practical guidelines for the prevention and management of COVID-19 in paediatric HSCT patients.
Please note: These guidelines are purely advisory and should be implemented in the context of advice from Dept of Health, your Trust management and Infection Control teams and will evolve as the situation changes.
The UK Myeloma Forum has released guidance on treating patients in the current COVID-19 pandemic.
This document has been produced in response to questions raised by cancer health care professionals relating to the administration of the Pfizer/BioNTech COVID-19 vaccine and the Oxford University/AstraZeneca COVID-19 vaccine in patients receiving SACT.
Remote pathways and priorities for care in pandemic times
The COVID‐19 pandemic, caused by the coronavirus SARS‐CoV‐2, has forced examination of much of routine healthcare provision in the UK, and necessitated changes in practice to protect patients from the virus while continuing to deliver high‐quality care for their other health needs. This has been highlighted by the challenges in provision of elective surgical services while SARS‐CoV‐2 remains prevalent in communities. NHS providers have moved from preoperative assessment pathways routinely involving face‐to‐face appointments to remote (telephone, digital or combination) assessments.1, 2 Telehealth‐based solutions provide an innovative option to provide patient care during pandemic times while helping prevent and contain the spread of infection.3 They are also convenient for the patient and medical staff and are likely to become part of routine care in the future. This reduction in face‐to‐face contacts means there is a pressing need to rethink how best to prepare patients for elective surgery, ensuring comprehensive assessment is performed within the limitations imposed by pandemic‐related changes to working practices. It is also an opportunity to review the evidence for best care to evaluate the benefit of certain aspects of what may have become routine practice in consideration of risk balance to the patient.
Click here to read the full guideline.
During the COVID-19 pandemic, it is important, that patients are able to still receive blood transfusions if and when needs be. This link contains information on current blood and platelets stocks and also other key resources from NHS Blood and Transplant and the National Blood Transfusion Committee included Emergency Blood shortage plans for hospitals.
Please click the link below to access the information:
Other Transfusion Resources: